165 related articles for article (PubMed ID: 20947927)
1. Low-dose acyclovir is effective for prevention of herpes zoster in myeloma patients treated with bortezomib: a report from the Korean Multiple Myeloma Working Party (KMMWP) Retrospective Study.
Kim SJ; Kim K; Do YR; Bae SH; Yang DH; Lee JJ
Jpn J Clin Oncol; 2011 Mar; 41(3):353-7. PubMed ID: 20947927
[TBL] [Abstract][Full Text] [Related]
2. Low-dose acyclovir prophylaxis for bortezomib-induced herpes zoster in multiple myeloma patients.
Minarik J; Pika T; Bacovsky J; Langova K; Scudla V
Br J Haematol; 2012 Oct; 159(1):111-3. PubMed ID: 22816982
[No Abstract] [Full Text] [Related]
3. Efficacy of continuous, daily, oral, ultra-low-dose 200 mg acyclovir to prevent herpes zoster events among bortezomib-treated patients: a report from retrospective study.
Aoki T; Nishiyama T; Imahashi N; Kitamura K
Jpn J Clin Oncol; 2011 Jul; 41(7):876-81. PubMed ID: 21616919
[TBL] [Abstract][Full Text] [Related]
4. Acyclovir to prevent reactivation of varicella zoster virus (herpes zoster) in multiple myeloma patients receiving bortezomib therapy.
Vickrey E; Allen S; Mehta J; Singhal S
Cancer; 2009 Jan; 115(1):229-32. PubMed ID: 19090004
[TBL] [Abstract][Full Text] [Related]
5. Bortezomib and bilateral herpes zoster.
di Meo N; Bergamo S; Dondas A; Trevisan G
Acta Dermatovenerol Alp Pannonica Adriat; 2012; 21(1):21-2. PubMed ID: 22584902
[TBL] [Abstract][Full Text] [Related]
6. Acyclovir prophylaxis against varicella zoster virus reactivation in multiple myeloma patients treated with bortezomib-based therapies: a retrospective analysis of 100 patients.
Swaika A; Paulus A; Miller KC; Sher T; Almyroudis NG; Ball D; Wood M; Masood A; Lee K; Chanan-Khan AA
J Support Oncol; 2012; 10(4):155-9. PubMed ID: 22222250
[TBL] [Abstract][Full Text] [Related]
7. Varicella-zoster virus prophylaxis with low-dose acyclovir in patients with multiple myeloma treated with bortezomib.
Pour L; Adam Z; Buresova L; Krejci M; Krivanova A; Sandecka V; Zahradova L; Buchler T; Vorlicek J; Hajek R
Clin Lymphoma Myeloma; 2009 Apr; 9(2):151-3. PubMed ID: 19406726
[TBL] [Abstract][Full Text] [Related]
8. Daily 500 mg valacyclovir is effective for prevention of Varicella zoster virus reactivation in patients with multiple myeloma treated with bortezomib.
Fukushima T; Sato T; Nakamura T; Iwao H; Nakajima A; Miki M; Sakai T; Kawanami T; Sawaki T; Fujita Y; Tanaka M; Masaki Y; Okazaki T; Nakajima H; Motoo Y; Umehara H
Anticancer Res; 2012 Dec; 32(12):5437-40. PubMed ID: 23225448
[TBL] [Abstract][Full Text] [Related]
9. Prophylactic antivirals may be helpful in prevention of varicella-zoster virus reactivation in myeloma, but are they safe?
Dasanu CA; Alexandrescu DT
J Oncol Pharm Pract; 2010 Dec; 16(4):266-8. PubMed ID: 19965947
[TBL] [Abstract][Full Text] [Related]
10. Late onset of bortezomib-associated cutaneous reaction following herpes zoster.
Varettoni M; Vassallo C; Borroni G; Mangiacavalli S; Zappasodi P; Rosso R; Lazzarino M; Corso A
Ann Hematol; 2007 Apr; 86(4):301-2. PubMed ID: 17131123
[No Abstract] [Full Text] [Related]
11. [Prophylaxis with acyclovir for herpes zoster infection during bortezomib-dexamethasone combination therapy].
Hasegawa Y; Kawahara F; Nagai H; Hirose T; Imai Y; Ishiguro T; Chou T
Rinsho Ketsueki; 2009 Jun; 50(6):488-94. PubMed ID: 19571509
[TBL] [Abstract][Full Text] [Related]
12. Bortezomib and the increased incidence of herpes zoster in patients with multiple myeloma.
Kim SJ; Kim K; Kim BS; Lee HJ; Kim H; Lee NR; Nam SH; Kwon JH; Kim HJ; Sohn SK; Won JH; Lee JH; Suh C; Yoon SS; Kim HJ; Kim I; Do YR; Lee WS; Joo YD; Shin HJ;
Clin Lymphoma Myeloma; 2008 Aug; 8(4):237-40. PubMed ID: 18765311
[TBL] [Abstract][Full Text] [Related]
13. Varicella-zoster virus prophylaxis with the traditional Chinese medicine Radix isatidis (Banlangen) in patients with multiple myeloma treated with bortezomib.
Guo H; Mao J; Qian X; Sun C; Sun H
J Altern Complement Med; 2011 Nov; 17(11):985-6. PubMed ID: 22087609
[No Abstract] [Full Text] [Related]
14. Analysis of herpes zoster events among bortezomib-treated patients in the phase III APEX study.
Chanan-Khan A; Sonneveld P; Schuster MW; Stadtmauer EA; Facon T; Harousseau JL; Ben-Yehuda D; Lonial S; Goldschmidt H; Reece D; Neuwirth R; Anderson KC; Richardson PG
J Clin Oncol; 2008 Oct; 26(29):4784-90. PubMed ID: 18711175
[TBL] [Abstract][Full Text] [Related]
15. Decrease in CD4+ T-cell counts in patients with multiple myeloma treated with bortezomib.
Heider U; Rademacher J; Kaiser M; Kleeberg L; von Metzler I; Sezer O
Clin Lymphoma Myeloma Leuk; 2010 Apr; 10(2):134-7. PubMed ID: 20371447
[TBL] [Abstract][Full Text] [Related]
16. Analysis of the efficacy and toxicity of bortezomib for treatment of relapsed or refractory multiple myeloma in community practice.
Wu KL; van Wieringen W; Vellenga E; Zweegman S; Lokhorst HM; Sonneveld P
Haematologica; 2005 Jul; 90(7):996-7. PubMed ID: 15996946
[TBL] [Abstract][Full Text] [Related]
17. Bortezomib in recurrent and/or refractory multiple myeloma. Initial clinical experience in patients with impared renal function.
Jagannath S; Barlogie B; Berenson JR; Singhal S; Alexanian R; Srkalovic G; Orlowski RZ; Richardson PG; Anderson J; Nix D; Esseltine DL; Anderson KC;
Cancer; 2005 Mar; 103(6):1195-200. PubMed ID: 15690325
[TBL] [Abstract][Full Text] [Related]
18. Optimizing bortezomib treatment in patients with relapsed multiple myeloma.
Richardson P
Clin Adv Hematol Oncol; 2006 May; 4(5):4-5; discussion 8; suppl 13. PubMed ID: 16832859
[No Abstract] [Full Text] [Related]
19. A phase 2 study of bortezomib in relapsed, refractory myeloma.
Richardson PG; Barlogie B; Berenson J; Singhal S; Jagannath S; Irwin D; Rajkumar SV; Srkalovic G; Alsina M; Alexanian R; Siegel D; Orlowski RZ; Kuter D; Limentani SA; Lee S; Hideshima T; Esseltine DL; Kauffman M; Adams J; Schenkein DP; Anderson KC
N Engl J Med; 2003 Jun; 348(26):2609-17. PubMed ID: 12826635
[TBL] [Abstract][Full Text] [Related]
20. [Safety evaluation of bortezomib in multiple myeloma patients with severe renal failure].
Muta T; Nakanishi H; Yasunaga M; Senba S; Murakami H; Kan S; Ueda Y; Fujisaki T
Gan To Kagaku Ryoho; 2011 Feb; 38(2):237-41. PubMed ID: 21368487
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]